NASDAQ
2.03USD
+0.01 (+0.50%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
154.3M
P/E
—
EPS
—
Beta
2.29
52W range
1.43-67
Day range
1.97–2.08
Open
2.04
Prev close
2.02
Volume
38.9K
Avg volume
93.3K
Dividend
0.00
IPO
2025-06-17
https://www.globenewswire.com/news-release/2026/07/23/3332361/0/en/Jyong-Biotech-Highlights-Multi-Billion-Dollar-Global-BPH-Market-Opportunity-and-Reaffirms-Strategic-Focus-on-Global-Licensing-Partnerships.html · 7/23/2026+0.80
https://www.globenewswire.com/news-release/2025/12/19/3208523/0/en/Jyong-Biotech-Responds-to-Share-Price-and-Volume-Movement.html · 12/19/2025+0.40
https://www.globenewswire.com/news-release/2025/08/22/3137831/0/en/Jyong-Biotech-Ltd-Participated-in-the-22nd-Urological-Association-of-Asia-Congress-to-Display-the-Clinical-Data-for-its-Phase-III-Studies-of-BOTRESO-and-Phase-II-Study-of-MCS-8-PCP.html · 8/22/2025+0.80
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
